In the present work, we investigated for the first time the antitumor activity of JAK2 ruxolitinib and HDAC inhibitor resminostat in the cytotoxicity, proliferation and apoptosis of CTCL cell lines, along with their impact in major cellular signaling pathways. This evidence concerns the gene JAK2 and primary cutaneous T-cell non-Hodgkin lymphoma.